Repligen corp stock.

Repligen Corporation Prices Public Offering of Shares of Common Stock. 6/27/2017. Summary. WALTHAM, Mass., June 27, 2017 (GLOBE NEWSWIRE) - Repligen Corporation ...Repligen Corp (RGEN-1.40%) Q3 ... 10 stocks we like better than Repligen When o ur award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for ...Our mission is to inspire advances in bioprocessing as a trusted partner in the production of biologic drugs that improve human health worldwide.Stock Price Forecast The 13 analysts offering 12-month price forecasts for Repligen Corp have a median target of 170.00, with a high estimate of 210.00 and a low estimate of 148.00.

Dimensional Fund Advisors LP raised its position in Repligen Co. (NASDAQ:RGEN – Free Report) by 8.2% during the 2nd quarter, HoldingsChannel.com …Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 24.63% in the past year. Currently, Repligen Corp’s price-earnings ratio is 60.3. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Repligen Corp Stock Price History. Repligen Corp’s price is currently down 21.75% so far this month. During the month of October, Repligen Corp’s stock price has reached a high of $164.24 and a low of $124.12. Over the last year, Repligen Corp has hit prices as high as $212.17 and as low as $134.64. Year to date, Repligen Corp’s stock is ...

Repligen Corp ( RGEN) receives a weak valuation ranking of 32 from InvestorsObserver data analysis. The proprietary ranking system focuses on the underlying health of a company through analysis of its stock price, earnings, and growth rate. RGEN has a better value than 32% of stocks based on these valuation analytics.

Repligen Corporation acquired Metenova AB for $173 million. Oct. 01: CI Repligen to Acquire Fluid Management Company Metenova Sep. 26: MT Repligen Corporation entered into a definitive agreement to acquire Metenova AB …Repligen Corp (NASDAQ:RGEN) 157.02 Delayed Data As of Nov 21 +1.38 / +0.89% Today’s Change 110.45 Today ||| 52-Week Range 200.98 -7.26% Year-to-Date Quote …As of February 13, 2023, Repligen Corp had a $10.2 billion market capitalization, compared to the Medical Equipment, Supplies & Distribution median of $331.8 million. Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 2.91% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.0.RGEN stock, belonging to Repligen Corp, has shown promising performance on October 31, 2023, based on the information provided. The data source for this analysis is CNN Money. According to the 13 analysts, the median target price for Repligen Corp is $195.00. The high estimate is $240.00, while the low estimate stands …4.08%. $2.65B. CureVac N.V. 1.85%. $1.21B. RGEN | Complete Repligen Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Nov 27, 2023 · CI. Transcript : Repligen Corporation Presents at The Stifel 2023 Annual Healthcare Conference, Nov-15-2023 08:00 AM. Nov. 15. CI. Repligen Insider Sold Shares Worth $557,328, According to a Recent SEC Filing. Nov. 13. MT. Deutsche Bank Cuts Repligen Price Target to $150 From $165, Maintains Hold Rating. Nov. 07.

Complete Repligen Corp. stock information by Barron's. View real-time RGEN stock price and news, along with industry-best analysis.

Repligen Corp’s ( RGEN) price is currently up 0.21% so far this month. During the month of March, Repligen Corp’s stock price has reached a high of $189.87 and a low of $171.57. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 34.02%.Complete Repligen Corp. stock information by Barron's. View real-time RGEN stock price and news, along with industry-best analysis.www .repligen .com. Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. 2014 The company is based in Waltham, Massachusetts, 2014 and incorporated in Delaware in 1981. [1] A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. [2] Stock RGEN November 29, 2023 NASDAQ 20 minutes delay $160.44 3.54 (2.256%) Open 157.9 ... Repligen Corporation | 28,921 followers on LinkedIn. FRAUD ALERT: Please take note that it has come to our ...One analyst has given the Repligen stock a sell rating, while five others have issued a buy rating on the firm, providing investors with mixed opinions regarding investment in this potentially promising industry player. ... Repligen Corp., a global life sciences company, has been making headlines recently with changes in ratings and price ...Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 24.63% in the past year. Currently, Repligen Corp’s price-earnings ratio is 60.3. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.

One analyst has given the Repligen stock a sell rating, while five others have issued a buy rating on the firm, providing investors with mixed opinions regarding investment in this potentially promising industry player. ... Repligen Corp., a global life sciences company, has been making headlines recently with changes in ratings and price ...Nov 30, 2023 · The latest Repligen stock prices, stock quotes, news, and RGEN history to help you invest and trade smarter. A vertical stack of three evenly spaced horizontal lines. ... Repligen Corp. is a ... Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.77% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.8. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Feb 24, 2023 · Repligen Corp’s ( RGEN) price is currently down 6.4% so far this month. During the month of February, Repligen Corp’s stock price has reached a high of $200.98 and a low of $164.04. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 34.51%. Repligen Corp’s ( RGEN) price is currently down 6.4% so far this month. During the month of February, Repligen Corp’s stock price has reached a high of $200.98 and a low of $164.04. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 34.51%.

Get the LIVE share price of Repligen Corp(RGEN) and stock performance in one place to strengthen your trading strategy in US stocks. Now Start Investing in Repligen Corp on Groww. Repligen Corp. Healthcare. $159.49 +2.59(1.65%) 1D. 1D. 1W. 1M. 1Y. 3Y. 5Y. Performance. Open Price: Prev. Close: Volume: Avg. Volume: $157.90: $156.90: 553,227:

UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report. November 14, 2023. Our mission is to inspire advances in bioprocessing as a trusted partner in the production of …Repligen Corp ( RGEN) receives a weak valuation ranking of 32 from InvestorsObserver data analysis. The proprietary ranking system focuses on the underlying health of a company through analysis of its stock price, earnings, and growth rate. RGEN has a better value than 32% of stocks based on these valuation analytics.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 27.1% in the past year. Currently, Repligen Corp’s price-earnings ratio is 68.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.The Growth Grade Winner: Repligen Corp. As you can clearly see from the Growth Grade breakdown above, Repligen Corp has a more attractive growth grade than Medtronic PLC. For investors who focus solely on how a company is growing relative to other companies in the same industry, Repligen Corp could be a good stock to add to their portfolio.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 7.77% in the past year. Currently, Repligen Corp’s price-earnings ratio is 81.2. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.Repligen Corp’s ( RGEN) price is currently down 28.2% so far this month. During the month of October, Repligen Corp’s stock price has reached a high of $164.24 and a low of $110.45. Over the last year, Repligen Corp has hit prices as high as $212.17 and as low as $118.08. Year to date, Repligen Corp’s stock is down 56.89%.Nov 30, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 7.08% in the past year. Currently, Repligen Corp’s price-earnings ratio is 78.5. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.

Repligen Corp. - RGEN STOCK NEWS . IMPACT. SENTIMENT. 11/14/2023 02:01 PM. RGEN: Nasdaq ... Repligen Corp. Nasdaq:RGEN. RGEN Rankings #1033 Ranked by Market Cap #4078 Ranked by Stock Gains. N/A Ranked by Dividends. RGEN Stock Data. Industry Biological Product (except Diagnostic) Manufacturing .

Repligen Corporation. Reports total third quarter revenues of $141.2 million, with base business revenues of $140.1 million. Narrows full year revenue guidance to range of $635-$645 million ...

Currently, there are 55.71 million shares of Repligen Corp stock available for purchase. Repligen Corp’s price-earnings (P/E) ratio is currently at 65.7, which is high compared to the Medical Equipment, Supplies & Distribution industry median of 37.9. The price-earnings ratio gauges market expectation of future performance by relating a stock ...Repligen's (RGEN) third-quarter earnings and revenues surpass estimates. The company tightens revenue guidance for 2023. Shares rise. Get the latest Repligen Corporation …Q3 2023 Repligen Corp Earnings Call finance.yahoo.com - November 1 at 10:15 AM. sfgate.com logo, Repligen: Q3 Earnings Snapshot sfgate.com - October 31 at 11 ...In a report released today, Puneet Souda from SVB Securities maintained a Buy rating on Repligen (RGEN – Research Report), with a price target of $200.00.The company’s shares opened today at ...RGN:MUN Munich Stock Exchange; RGN:STU Stuttgart Stock Exchange; RGEN:DEU German Composite; RGN:FRA Frankfurt Stock Exchange; RGN:DUS Dusseldorf Stock Exchange; ... Repligen Corp BUILDING 1, SUITE 100, 41 SEYON STREET WALTHAM 02453 United States USA; Phone +1 (781) 449-9560; Fax +1 (302) …Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock...Oct 13, 2023 · Avantor Inc does not currently pay a dividend. Currently, Repligen Corp’s price-earnings ratio is 63.2. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%. Analysts expect adjusted earnings to reach $1.748 per share for the current fiscal ... Repligen Corp stock has a Growth Score of 82, Estimate Revisions Score of 38 and Quality Score of 71. Comparing Abbott Laboratories and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not.Repligen Corp’s ( RGEN) price is currently up 23.95% so far this month. During the month of July, Repligen Corp’s stock price has reached a high of $177.18 and a low of $134.64. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $134.64. Year to date, Repligen Corp’s stock is down 33.79%.Reports first quarter revenue of $182.7 million, with base business growth of 4% as reported and 7% at constant currency Reports first quarter gross margin of 55.2% on both GAAP and adjusted (non-GAAP) basis Closed on acquisition of single-use bag manufacturer FlexBiosys Inc. in April WALTHAM, Mass., May 02, 2023 (GLOBE …Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 27.1% in the past year. Currently, Repligen Corp’s price-earnings ratio is 68.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.

Get the latest Repligen Corporation (RGEN) stock news and headlines to help you in your trading and investing decisions. Sep 22, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.25% in the past year. Currently, Repligen Corp’s price-earnings ratio is 66.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%. 6 hours ago · According to 7 analyst offering 12-month price targets in the last 3 months, Repligen has an average price target of $186.71 with a high of $210.00 and a low of $165.00. Instagram:https://instagram. books on the 2008 crashdefinition short a stocknanotechnology stocksbest apps for real estate investors View the latest Repligen Corp. (RGEN) stock price, news, historical charts, analyst ratings and financial information from WSJ. enbridge stock forecasthow much is pizza Dec 4, 2023 · × Funding Description. Security: Description: Exchange: SYMBOL: Common stock, $0.01 par value: EXCHANGE bank apps list Repligen Corp. (US:RGEN) has 1047 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 71,198,355 shares.Find the latest Repligen Corporation (RGEN) stock quote, history, news and other vital information to help you with your stock trading and investing. Nov 3, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 12.34% in the past year. Currently, Repligen Corp’s price-earnings ratio is 74.0. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.